Kovovax begins trial in India, expected to be launched by September: Poonawala

Poonawala said in January this year that SII hopes that Kovovax will be introduced by June 2021.  (File pic)

Poonawala said in January this year that SII hopes that Kovovax will be introduced by June 2021. (File pic)

Covid-19 Vaccine: Adar Poonawala hoped that this vaccine could be introduced by September this year. In August 2020, the US vaccine company Novax Inc. announced a license agreement with SII.

new Delhi. Serum Institute of India Chief Executive Officer (CEO) Adar Poonawala said on Saturday that clinical trials of Covid-19 Vaccine Covax have begun in India. . He hoped that this vaccine could be introduced by September this year. In August 2020, the US vaccine company Novax Inc. announced a license agreement with SII. Novavax has signed this agreement for the development and commercialization of its Kovid-19 vaccine ‘Candidate’ NVX-CO 2373. This vaccine will be made available to India and countries in the lower and middle income groups.

Poonawala tweeted, “Trial of Kovovax has started in India. This vaccine is being developed in partnership with Novavax and Serum Institute. This vaccine has been tested against Kovid-19 variants in Africa and Britain. Its total efficiency is found to be 89 percent. We hope that this vaccine will be introduced by September 2021. ”

Also read- Why is it difficult to make medicines that kill viruses?

However, the commercial agreement between Novavax and SII does not include upper-middle and high-income countries. Novavax owns the vaccine for these countries. Poonawala said in January this year that SII expects Kovovax to be rolled out by June 2021. SII is already supplying the Kovid-19 vaccine ‘Kovishield’ to AstraZeneca / Oxford in India and many countries of the world.
(Disclaimer: This news has been published directly from the Syndicate feed. It has not been edited by the News18Hindi team.)




Leave a Reply

Your email address will not be published. Required fields are marked *